EcoDrugPlus

Mdm2 Proto-Oncogene

Ensembl ID : ENSSARG00000005801
Gene Symbol: MDM2
1 External references
262 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSSARG00000007183
Gene Symbol: MET
1 External references
211 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSSARG00000011909
Gene Symbol: NQO1
1 External references
195 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSSARG00000010915
Gene Symbol: NFE2L2
3 External references
216 Possible Orthologues:

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSARG00000008832
Gene Symbol: PIM2
1 External references
115 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSSARG00000003535
Gene Symbol: RELA
1 External references
199 Possible Orthologues:

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSSARG00000012349
Gene Symbol: ROS1
1 External references
124 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSARG00000007569
Gene Symbol: RAF1
1 External references
216 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSSARG00000011391
Gene Symbol: ROCK1
1 External references
215 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSSARG00000002178
Gene Symbol: ROCK2
1 External references
304 Possible Orthologues:

Sem1 26s Proteasome Subunit

Ensembl ID : ENSSARG00000005688
Gene Symbol: SEM1
1 External references
155 Possible Orthologues:

Tek Receptor Tyrosine Kinase

Ensembl ID : ENSSARG00000007431
Gene Symbol: TEK
1 External references
164 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).